ClinicalTrials.gg

Program

tarperprumig

Also written as “Tarperprumig”, “ALXN1820” and “ALXN1820 SC”.

Its studies are mostly in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Anemia, Sickle Cell, led by AstraZeneca.

Furthest: phase 2, since Sep 15, 20223 company-led studies, 1 open or runningNext primary completion: Oct 11, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca31 open or runningphase 2since Sep 15, 2022Nov 13, 2020Oct 11, 2027phase 2 · NCT07160608
  • Named in AstraZeneca’s own pipeline as tarperprumig, phase 2, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2020First study: phase 1 study in HealthyFirst studyNCT04631562 · 66 enrolled · Australia, United Kingdom
  2. Sep 15, 2022Phase 2 study in Anemia, Sickle CellNCT05565092 · 2 enrolled · United States
  3. Jul 21, 2025Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07160608 · 78 enrolled · Argentina, Australia, Brazil and more

Ahead

  1. Oct 11, 2027Primary completion: phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07160608

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Argentina, Australia, Brazil and more2Active, not recruitingOct 11, 202778
NCT05565092Anemia, Sickle Cell · United States2TerminatedJan 9, 20242
NCT04631562Healthy · Australia, United Kingdom1CompletedSep 1, 202266

How it is read

Names in the registry

  • “Tarperprumig”, 1 entry
  • “ALXN1820”, 1 entry
  • “ALXN1820 SC”, 1 entry
  • “ALXN1820 IV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.